# Bladder Cancer Bladder cancer is the tenth most common cancer globally. Most cases are urothelial carcinomas arising from the bladder lining. Recurrence is a major problem, especially in non-muscle-invasive disease. That makes prevention and adjunctive strategies more interesting here than in many other cancer types. Urolithin A has now been studied in two independent bladder-cancer cell-line papers. That matters. This is not a one-study signal. One comparative study also reported something unusual. **UMUC3 bladder-cancer cells were the most sensitive of all cancer cell lines tested in that experiment.** That finding comes from a single study. It still deserves mention. All current evidence is preclinical. There are no bladder-cancer clinical trials. ### Why bladder cancer is a physiologically logical target Bladder cancer has a pharmacokinetic logic that is worth taking seriously. After absorption, Urolithin A and its conjugated metabolites are excreted in urine. That means the urothelium is exposed to these metabolites during normal urinary transit. Very few cancer types have that kind of direct post-absorption exposure route. This does **not** prove therapeutic concentrations reach bladder tumours. That part remains unmeasured. Even so, the exposure logic is coherent. It resembles the local-exposure rationale discussed on the [Colorectal Cancer](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/colorectal-cancer.md) page, although the route is different. ### Study 1 — UMUC3 cells The first study compared ellagic acid with urolithins A, B, and C across several tumour cell lines. UMUC3, an invasive bladder-cancer line, stood out. #### Highest sensitivity across the tested cancer panel UMUC3 cells showed the lowest IC50 values for Urolithin A among the tested cancer lines. Urolithin A was also more active than Urolithin B, Urolithin C, and ellagic acid in this model. That is a useful comparative result. It suggests bladder-cancer biology may contain a particularly vulnerable subset. The study does not prove why. One plausible explanation is UMUC3's **HRAS**-driven signalling profile. That remains a hypothesis rather than a confirmed mechanism. #### Antiproliferative activity Urolithin A inhibited UMUC3 proliferation in a dose-dependent way. This was the strongest growth-suppression signal among the compared compounds in the same model. #### G2/M cell-cycle arrest Urolithin A induced clear G2/M arrest in UMUC3 cells. That fits a recurring pattern already seen in other Urolithin A cancer pages, including [Endometrial Cancer](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/endometrial-cancer.md). The bladder result looked especially pronounced in this line. #### Apoptosis induction Annexin V and propidium iodide analysis showed increased apoptotic cell death after Urolithin A treatment. Both early and late apoptosis increased. That moves the result beyond simple growth slowing. It suggests active tumour-cell elimination. #### PI3K/AKT and MAPK suppression The same study found suppression of both the **PI3K/AKT** and **MAPK** pathways. That is mechanistically important in UMUC3 cells. **HRAS** can signal through both pathways. So dual suppression could help explain why this line appears unusually sensitive. That explanation is biologically coherent. It has not yet been directly validated by HRAS-focused experiments. ### Study 2 — T24 cells A second study used **T24** bladder-cancer cells. This matters because it shows the signal is not restricted to one line. In T24 cells, Urolithin A showed: * stronger antioxidant activity than ellagic acid * dose-dependent antiproliferative activity * greater potency than ellagic acid in both assays This is a simpler paper mechanistically. Even so, it provides independent replication of bladder-cancer relevance. That alone strengthens the page. ### MEKK1, c-Jun, p38, and PPAR-γ The 2025 oncology review added more mechanistic detail from the published bladder work. The reported pattern includes: * lower **MEKK1** * lower **phospho-c-Jun** * higher **phospho-p38 MAPK** * higher **PPAR-γ** This combination is meaningful. **MEKK1** sits upstream of stress-signalling cascades. Lower MEKK1 and lower phospho-c-Jun suggest weaker JNK-linked survival and proliferation signalling. Higher **phospho-p38** points the other way. In this context, it supports a stronger stress-apoptosis response. That means Urolithin A may not just suppress growth pathways. It may also re-route stress signalling toward cell death. **PPAR-γ** is also worth noting. PPAR-γ activation is associated with differentiation and antiproliferative effects in urothelial cancer biology. So this gives bladder cancer a second mechanistic layer beyond kinase suppression. #### TEM confirmation of apoptosis The review also notes transmission electron microscopy findings consistent with apoptosis. That included chromatin condensation and nuclear fragmentation. This is a useful methodological detail. It supports the apoptosis conclusion at the structural level rather than relying on one assay type. ### BCG context Bladder cancer raises one additional question that has not been tested yet. High-risk non-muscle-invasive disease is often treated with **BCG** immunotherapy after transurethral resection. BCG works through local immune activation in the bladder. That includes innate and adaptive immune responses. Urolithin A has immune-relevant biology that could matter here. Its broader effects on NK cells and CD8-positive T cells are covered on the [Immune Effects](/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/immune-effects.md) page. Whether that could complement BCG, or matter in BCG-unresponsive disease, has not been studied. It is a logical research question. It remains untested. ### Urinary excretion matters here Urolithin A glucuronide and sulfate conjugates are detectable in urine after ellagitannin intake or direct supplementation. That gives bladder cancer an unusual exposure advantage. The urothelium is repeatedly bathed in urine. So bladder tumours may be exposed to Urolithin A-related metabolites during transit. This is still only a pharmacokinetic rationale. No human study has yet shown that bladder-tissue concentrations reach the levels used in cell culture. Still, this is one of the more tractable open questions in the whole Urolithin A field. ### What remains unknown Several gaps still matter. * no xenograft or orthotopic bladder-cancer studies * no direct test of whether **HRAS** mutation status drives sensitivity * no direct measurement of urothelial tumour exposure after oral dosing * no combination work with BCG, cisplatin-based chemotherapy, or checkpoint inhibitors * no separation yet between non-muscle-invasive and muscle-invasive disease contexts * no clinical trials in bladder-cancer patients ### Bottom line Bladder cancer is one of the more interesting emerging Urolithin A pages. That is not because it has the largest evidence base. It is because the current findings line up unusually well. The strongest takeaways are: * two independent studies support bladder-cancer activity * **UMUC3** cells were unusually sensitive in a cross-cancer comparison * Urolithin A caused G2/M arrest and apoptosis in UMUC3 cells * it suppressed both **PI3K/AKT** and **MAPK** signalling * urinary excretion gives bladder cancer a plausible exposure route that most tumour types do not have The evidence is still fully preclinical. Even so, bladder cancer now looks like a biologically credible target for further Urolithin A work. ### Evidence level summary | Finding | Evidence type | Confidence | | ------------------------------------------------- | --------------------------------- | -------------------------------------------------- | | Highest sensitivity among tested cancer lines | In vitro comparative study, UMUC3 | Early preclinical | | G2/M arrest and apoptosis induction | In vitro, UMUC3 | Early preclinical | | Dual PI3K/AKT and MAPK suppression | In vitro, UMUC3 | Early preclinical | | Antiproliferative and antioxidant activity | In vitro, T24 | Early preclinical, second line | | MEKK1 and c-Jun suppression with p38 upregulation | In vitro | Early preclinical | | PPAR-γ upregulation | In vitro | Early preclinical | | Urinary excretion of Urolithin A metabolites | Human pharmacokinetic data | Confirmed exposure route, tissue relevance unknown | | In vivo bladder-tumour evidence | Not studied | Major gap | | BCG-combination relevance | Not studied | Logical but untested | | Clinical evidence in bladder-cancer patients | None | No evidence | ### References Urolithins impair cell proliferation, arrest the cell cycle and induce apoptosis in UMUC3 bladder cancer cells In vitro antioxidant and antiproliferative effects of ellagic acid and its colonic metabolite urolithins on human bladder cancer T24 cells Unveiling the potential of Urolithin A in cancer therapy — mechanistic insights to future perspectives Urolithins: the gut-based polyphenol metabolites of ellagitannins in cancer prevention {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/bladder-cancer.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.